Loading clinical trials...
Loading clinical trials...
A Phase II Study of Nivolumab in Combination With Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Conditions
Interventions
Nivolumab
Ixazomib
+2 more
Locations
2
United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Mass General/North Shore Cancer Center
Danvers, Massachusetts, United States
Start Date
February 14, 2020
Primary Completion Date
November 12, 2020
Completion Date
March 30, 2022
Last Updated
August 21, 2023
NCT04973605
NCT05862012
NCT06138275
NCT06285318
NCT07391657
NCT07284758
Lead Sponsor
Andrew Yee, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions